41340-88-9 Usage
General Description
PIPERAZIN-1-YL-PIPERIDIN-1-YL-METHANONE is a chemical compound with a unique molecular structure. It is used as a building block in the synthesis of various pharmaceuticals and organic compounds. The presence of both piperazine and piperidinyl groups in the molecule gives it potential applications in medicinal chemistry. It may be used in the development of new drugs for a variety of conditions, including psychiatric disorders and neurological diseases. Additionally, its structural features make it a valuable intermediate in the production of diverse organic compounds, including agrochemicals, dyes, and fragrances. As a versatile and multifunctional chemical, PIPERAZIN-1-YL-PIPERIDIN-1-YL-METHANONE has the potential for wide-ranging utility in the field of chemistry and pharmaceutical research.
Check Digit Verification of cas no
The CAS Registry Mumber 41340-88-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,1,3,4 and 0 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 41340-88:
(7*4)+(6*1)+(5*3)+(4*4)+(3*0)+(2*8)+(1*8)=89
89 % 10 = 9
So 41340-88-9 is a valid CAS Registry Number.
InChI:InChI=1/C10H19N3O/c14-10(12-6-2-1-3-7-12)13-8-4-11-5-9-13/h11H,1-9H2
41340-88-9Relevant articles and documents
Thienopyrimidine and furan and pyrimidine derivatives, its preparation process and its use in medicine
-
Paragraph 0160-0162, (2016/10/09)
Disclosed are thienopyrimidine and furopyrimidine derivatives, the preparation method thereof and the medical use thereof. The derivatives have a structure as shown in formula V. The thienopyrimidine and furopyrimidine derivatives provided in the present invention have dominant EGFR inhibiting activity, and some of these compounds also have dominant inhibiting activity against VEGFR; therefore, same can expect to be developed as tyrosine kinase EGFR and/or VEGFR inhibitors, and to be used for preparing the drugs for preventing or treating the diseases related to epidermal growth factor receptor EGFR and/or vascular endothelial growth factor receptor VEGFR. Provided is a new development direction and approach for developing novel tyrosine kinase inhibitor drugs having low drug resistance or able to relieve drug resistance to the inhibitor in the early stages, thereby having extensive application prospects and medical value.
